Lung cancer screening intervals based on cancer risk

被引:4
|
作者
Zhang, Li [1 ,2 ]
Yip, Rowena [2 ]
Jirapatnakul, Artit [2 ]
Li, Meng [1 ,2 ]
Cai, Qiang [2 ,3 ]
Henschke, Claudia, I [2 ,4 ]
Yankelevitz, David F. [2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Diagnost Radiol, Natl Canc Ctr, Natl Clin Res Ctr,Canc Canc Hosp, Beijing 100021, Peoples R China
[2] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA
[3] Shanxi Prov Peoples Hosp, Dept Radiol, Taiyuan 030012, Shanxi, Peoples R China
[4] Vet Adm Hlth Care Syst, Phoenix, AZ USA
关键词
Volume doubling time; Tumor aggressiveness; Risk prediction model; CT screening; PULMONARY NODULES; CT; TRIAL; MORTALITY; PROBABILITY; BENEFITS;
D O I
10.1016/j.lungcan.2020.09.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: As low-dose CT screening is gaining acceptance, focus is on increasing the efficiency of screening. One major consideration is to reduce the total number of annual rounds by increasing the interval between screening rounds. It has been suggested that longer intervals could be used for individuals who are at lower risk of lung cancer. In this study, we explored whether eligible participants in a program of LDCT screening who are at lower risk of lung cancer have less aggressive cancers than those at higher risk. Methods: We retrospectively identified 118 participants in I-ELCAP database between 1992-2019 who had been screened using HIPAA-compliant protocols and had solid lung cancers diagnosed on an annual round of screening, 7-18 months after the prior round. Volume doubling time (VDT) for each cancer was calculated. Estimated risk of developing lung cancer was calculated using PLCOM2012 model. The strength of the relationship between VDT and individual PLCOM2012 scores was assessed by Pearson(r) and Spearman (rho) correlation coefficients. Results: VDTs were significantly different by cell-type (p < 0.0001); median VDT for small cell was 34.0 days, followed by other cell-types (61.8 days), squamous-cell (73.3 days), and adenocarcinoma (135.7 days). The median VDT for the 78 (66.1 %) Stage I lung cancers was significantly longer than the 40 Stage II + lung cancers (101.4 days vs. 45.5 days, p < 0.0001). None of the established lung cancer risk indicators (age, pack-years of smoking, or PLCOM2012 scores) were significant predictors of VDT or lung cancer stage. Conclusion: No significant relationship was demonstrated between risk of developing lung cancer (measured by risk models, age or smoking history) and lung cancer aggressiveness (measured by VDT, cell-type and Stage). This suggests that there is no evidence for determining intervals between repeat screenings using risk-based characteristics. It does not, however, exclude the possibility that future models may establish such a relationship.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [21] EXAMINING THE EFFECT OF CANCER RISK AND PATIENT PREFERENCES ON THE NET BENEFIT OF LUNG CANCER SCREENING: A PERSONALIZED LUNG CANCER SCREENING MODEL
    Caverly, Tanner
    Cao, Pianpian
    Hayward, Rodney A.
    Meza, Rafael
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S219 - S219
  • [22] Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening
    Nofal, Sara
    Niu, Jiangong
    Resong, Paul
    Jin, Jeff
    Merriman, Kelly W.
    Le, Xiuning
    Katki, Hormuzd
    Heymach, John
    Antonoff, Mara B.
    Ostrin, Edwin
    Wu, Jia
    Zhang, Jianjun
    Toumazis, Iakovos
    [J]. CANCER MEDICINE, 2024, 13 (05):
  • [23] Assessing lung cancer risk in young and elderly patients in a lung cancer screening programme
    Campo Ezquibela, Aranzazu
    Ortiz, Begona
    Belen Alcaide, Ana
    Berto, Juan
    Perez-Warnisher, Teresa
    Felgueroso, Carmen
    Pueyo, Jesus
    Ocon, Marimar
    Pablo De Torres, Juan
    Bastarrika, Gorka
    Seijo, Luis
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [24] Lung Cancer Screening: Association of Lung Cancer Susceptibility and Risk with Decisional Conflict and Distress
    Schweiger, L.
    Tostado, P. R.
    Golden, S.
    Melzer, A. C.
    Datta, S.
    Sullivan, D. R.
    Slatore, C. G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [25] LUNG CANCER RISK PROFILES AND ELIGIBILITY OF ATTENDEES IN A LUNG CANCER SCREENING DEMONSTRATION PILOT
    Ruparel, M.
    Dickson, J. L.
    Quaife, S. L.
    Bhowmik, A.
    Taylor, M. N.
    Ahmed, A.
    Shaw, P. J.
    Burke, S.
    Soo, M. J.
    Devaraj, A.
    Navani, N.
    Duffy, S. W.
    Baldwin, D. R.
    Waller, J.
    Janes, S. M.
    [J]. THORAX, 2017, 72 : A11 - A12
  • [26] Association of Race With Lung Cancer Risk Among Adults Undergoing Lung Cancer Screening
    Shusted, Christine S.
    Evans, Nathaniel R.
    Juon, Hee-Soon
    Kane, Gregory C.
    Barta, Julie A.
    [J]. JAMA NETWORK OPEN, 2021, 4 (04)
  • [27] Lung Cancer Screening Does Not Shorten Intervals From Imaging to Treatment of Lung Cancer Compared to General Community Approaches
    Freedman, Zachary
    Salzano, Richard
    Feinn, Richard
    [J]. CHEST, 2017, 152 (04) : 631A - 631A
  • [28] Lung Nodule Cancer Risk In The National Lung Screening Trial
    Nair, V. S.
    Sundaram, V.
    Desai, M.
    Gould, M. K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [29] Performance of the Cancer Risk Management Model Lung Cancer Screening Module
    Flanagan, William M.
    Evans, William K.
    Fitzgerald, Natalie R.
    Goffin, John R.
    Miller, Anthony B.
    Wolfson, Michael C.
    [J]. HEALTH REPORTS, 2015, 26 (05) : 11 - 18
  • [30] Retrospective Predictive Performance of a Lung Cancer Screening Risk Prediction Model in a Clinical Lung Cancer Screening Program
    Kitts, Andrea Borondy
    Regis, Shawn
    Mckee, Andrea
    Sands, Jacob
    Mckees, Brady
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S356 - S356